TPA gene therapy (Baylor/Sinai)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameTPA gene therapy (Baylor/Sinai)
Drug Alias Nameadenoviral-tPA construct (Baylor/Mount Sinai)myocardial infarction gene therapy (Baylor/Mount Sinai)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector
Mechanisms of ActionFibrinolysis stimulantsPlasminogen activators modulators
TargetsPlasminogen activators
Therapy Area/IndicationsThromboembolismMyocardial Infarction
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBaylor College Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBaylor College Of MedicineMount Sinai School Of Medicine
Active IndicationsN/A
Inactive IndicationsThromboembolismMyocardial Infarction

Other Information

ATC CodeN/A
Related LinksN/A